Download This Paper
Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com.
Comparative Efficacy and Safety of Pharmacological Interventions for the Treatment of COVID-19: A Systematic Review and Network Meta-Analysis of Confounder-Adjusted 36813 Hospitalized Patients
61 Pages Posted: 21 Jul 2020
More...Abstract
Background: No evidence-based guideline exists for pharmacological management of COVID-19.
Methods: We conducted a random-effects network meta-analysis of randomized controlled trials (RCTs) and baseline-adjusted observational studies to identify optimal pharmacological treatment of COVID-19. We searched PubMed, Google Scholar, MEDLINE, the Cochrane Library, medRxiv, SSRN, WHO International Clinical Trials Registry Platform, and ClinicalTrials.gov from inception to May 2020. The primary outcomes were mortality, progression to severe course or admission to intensive care unit (ICU), time to viral clearance, QT prolongation, fatal cardiac complications, and non-cardiac serious adverse events. Effect size measures were odds ratios (OR) and mean differences (MD), with 95% confidence intervals (95% CI). The certainty of evidence was assessed using GRADE framework. This study is registered with PROSPERO, number CRD42020186527.
Findings: 40 studies including a total of 114,371 hospitalized COVID-19 patients (36,813 confounder-adjusted patients) were included for analysis. Remdesivir and hydroxychloroquine demonstrated efficacy for non-ICU patients with COVID-19 as remdesivir reduced disease progression (OR 0·31, 95% CI 0·18 to 0·55, high certainty) while hydroxychloroquine reduced the time to viral clearance compared to standard care (MD -3·84 days, 95% CI -5·78 to -1·90, moderate certainty). However, the combination of hydroxychloroquine and azithromycin was shown to be associated with increased QT prolongation incidence and fatal cardiac complications in cardiac-impaired population (OR 1·85, 95% CI 1·05 to 3·26 and OR 8·08, 95% CI 1·37 to 47·65, respectively, low certainty), and thus hydroxychloroquine monotherapy is preferable to combination therapy. For ICU-based critically ill patients, high dose IVIG (low certainty) and tocilizumab (very low certainty) may reduce mortality while corticosteroids (moderate certainty) may increase mortality.
Interpretation: individualized treatment strategies based on clinical setting and target outcome should be implemented. The gradient of evidence levels presented in this review may be used to assist decision-making of clinicians and policy makers.
Funding Statement: None.
Declaration of Interests: All authors have no potential or actual conflict of interest.
Keywords: COVID-19; hydroxychloroquine; Remdesivir; IVIG; steroid; Mortality; viral clearance; network meta-analysis
Suggested Citation: Suggested Citation